Corporate Update & 2025 Outlook

Tekcapital

13/03/2025 07:00

RNS Number : 4224A

GenIP PLC

13 March 2025

 

 

 

13 March 2025 

 

GenIP Plc

("GenIP" or the "Company")

 

Corporate Update

 

GenIP plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to provide the following corporate update and outlook for the year ahead.

 

Highlights

 

●    Significant Commercial Progress: Since the launch of GenAI enhanced services in September 2024, GenIP has secured Invention Evaluator orders (including prepaid advance orders for future drawdown) for over 450 analytical assessments and has completed two Vortechs executive hires with four new searches underway.

 

●    Robust Order Pipeline: Following the launch of an extensive marketing campaign in December 2024, the Company has received a number of promising leads and believes the conversion of its current sales pipeline will lead to a step-change in order flow and revenue generation.

 

●    Global Expansion: International interest in GenIP's solutions is growing. The Company has delivered Invention Evaluator reports to organisations in over 25 countries across six continents, and the pipeline continues to expand to new territories. Demonstrating the global appeal of its services, GenIP has significant bids in progress with two leading institutions in Asia following our participation in a major industry event in the region.

 

●    Product Development: As a result of deep engagement with new and existing customers, GenIP is developing a new range of AI-enhanced solutions to serve the technology transfer market. It is intended that GenIP's new products will leverage the existing AI analytics infrastructure and complement current offering by meeting additional requirements of research organisations seeking to accelerate the commercialisation of their technological discoveries.

 

 

AUTM 2025 Annual Meeting

 

Building on recent event sponsorships in Asia and Latin America that led to new Invention Evaluator orders, GenIP sponsored and attended the AUTM Annual Meeting in the US in March 2025. AUTM is a leading global platform for advancing knowledge in Intellectual Property, Technology Transfer, and Innovation. GenIP connected with representatives of universities, research institutions, corporations, and investment firms and believes the event will result in additional orders.

 

 

2025 Outlook

 

GenIP is well-positioned to capitalise on the growing demand for AI-enhanced solutions in the technology transfer market. The Company has clear revenue visibility, a strong order book, and a growing sales pipeline. GenIP is actively collaborating with the industry to continuously improve its services and is pursuing the expansion of its offering with new products nearing their launch. Customers pay in advance for Invention Evaluator report orders, providing the Company with operating cash flow and future revenue visibility, with revenue recognised upon report production by GenIP and delivery to the client. Typically, prepayments are utilised approximately 50% within the first 12 months and the balance over the following 12-18 months. Historically, there was no time limit for utilisation of the prepaid reports. To accelerate the utilisation the Company has implemented new strategies including a fixed period during which the prepaid orders need to be used. Our expanding client base and the anticipated introduction of new products position the Company favourably for significant growth. GenIP retains ample financial flexibility to capitalise on emerging opportunities.

 

Since the last corporate update, GenIP has completed two executive search assignments and secured four new searches. The Directors anticipate increasing demand for Vortechs services as a result of the ongoing marketing efforts and the current prospective assignments being progressed.

 

Lord Willetts, Chairman of GenIP, commented:

 

"As Chairman of the Board, I'm delighted to see GenIP's solid commercial progress and global reach, which is a testament to the value our AI-enhanced solutions bring to the technology transfer market. The combination of sophisticated analytics with expert human insights has the potential to be a winning formula, providing support to universities and corporations in navigating the complexities of commercialising innovation. In a world where the pace of technological advancement is ever-increasing, GenIP is well-positioned to play a role in ensuring that the most promising discoveries reach their potential."

 

For further information regarding GenIP, please visit www.genip.ai, or contact:

 

GenIP Plc
Melissa Cruz, CEO
Via Redchurch Communications
Beaumont Cornish Limited (Nominated Adviser)
Roland Cornish / Asia Szusciak / Andrew Price
Tel: +44 (0) 20 7628 3396
Novum Securities Limited (Broker)
Jon Belliss
Tel: +44 (0)20 7399 9425
JBelliss@novumsecurities.com
Redchurch Communications (Financial PR)
John Casey
genip@weareredchurch.com

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

Notes to Editors

Your browser does not support HTML5 video.

 

About GenIP

 

GenIP provides generative artificial intelligence (GenAI) analytic services to help companies, research institutions and venture funds assess and commercialise new discoveries. GenIP combines expert human technical review with GenAI algorithms to provide insightful and verified services.

 

GenIP provides two complementary platform-based services:

1.   Invention Evaluator: Provides bespoke research reports that assess the market potential of new technological innovations and discoveries using AI-driven proprietary software; and

 

2.   Vortechs: which is an executive recruitment platform that through advanced machine learning algorithms and natural language processing technologies assists in matching technology organisations with experienced executives skilled in technology commercialisation.

 

The Company believes that its integrated GenAI service offerings will help organisations to evaluate and commercialise their technological innovations. 

Company Strategy

GenIP's goal is to be a leading Generative AI analytic services company. To achieve this, the Company has established three strategic pillars:

 

●    Organically grow Invention Evaluator and Vortechs' revenue through institutional and corporate connections as well as increase client pipeline through marketing, advertising and social media spend.

●    Expand the Generative AI service offerings within Invention Evaluator and Vortechs' to reach new customers and improve margins.

●    Bolt-on acquisitions of additional Generative AI services that are helpful to our clients and have demonstrated initial market traction. 

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
UPDJTMITMTTBBIA